All The Week

Recent Discovery on Mechanism that Causes Cancer Cells to Self-Destruct Published on Oncotarget

A high number of cancer patients have to endure the unpleasant effects associated with chemotherapy, as it is the most prescribed method of treating cancer. Patients suffering from pancreatic cancer and other forms of belligerent cancers have to endure it as there is still no other known efficient therapy. A new study conducted in Tel Aviv University (TAU) suggests that there are three proteins that can help in killing cancerous cells as they divide. The results of the study were published in Oncortaget in the month of February this year. Oncotarget is published by Impact Journals

Focus on the Research

Malka Cohen-Armon from the Sackler School of Medicine, TAU led the research which established that proteins can be modified specifically during the mitosis process. This brings about the inherent mechanism of death that leads to the eradication of duplicating cancerous cells. Prof. Cohen stated that the discovery of this mechanism that destroys the cancer cells without harming the healthy cells is pretty exciting. Learn more about Oncotarget journal at

He added that the study proved that the faster the rate at which cancer cells proliferate, the faster and effectively they will be destroyed. This mechanism will prove useful and efficient in the treatment of aggressive cancers that remain defiant even when exposed to traditional chemotherapy. The experiments used in the study were carried out on cell cultures of various incurable cancer types like lung, breast, colon, blood, pancreas and brain. He concluded by saying that the new discovery would impact positively on the ongoing and existing cancer research by bringing a new target mechanism on specific cancer cells thereby eradicating them. [Read More]

About Oncotarget

Oncotarget is an open-access peer-reviewed medical journal that covers research on various oncology aspects. It was founded in 2010 and is published by the Impact Journals. Its editors-in-chief are Andrei V. Gudkov and Mikhail Blagosklonny (Roswell Park Cancer Institute). Oncotarget has seen its popularity rise continuously over the years due to its reputation of being constructive, punctual, insightful and its multiple peer-review aspect. All these qualities help the medical journal’s authors to widen their impact on cancer research. Oncotarget focuses mainly on the pathological basis for cancers, treatment protocols and prospective targets for therapy, which are aimed at improving the care given to cancer patients.

Read more: